MOTS-c Compounding Legal Status: What the FDA Has and Has Not Approved

What Is MOTS-c and Where Does It Come From?

MOTS-c (Mitochondrial Open Reading Frame of the Twelve S rRNA type-c) is a 16-amino-acid peptide encoded by the mitochondrial genome. It was first characterized by Lee et al. In 2015 in Cell Metabolism, where the research team showed it improved insulin sensitivity and reduced obesity in mice on a high-fat diet. That single paper opened significant clinical interest.

The peptide is not a hormone in the classical sense. It acts more like a signaling molecule, crossing from mitochondria into the nucleus to regulate metabolic gene expression through the AMPK pathway. Lee C, Zeng J, Drew BG, et al., Cell Metabolism 2015.

Why Regulatory Status Matters for a Mitochondrial Peptide

Because MOTS-c is synthesized exogenously for research purposes, any preparation intended for human administration immediately falls under FDA drug-product regulations. A compound does not need an approved NDA or BLA to be regulated; the act of manufacturing and distributing it for therapeutic use makes it subject to Section 501, 502, and 503 of the Federal Food, Drug, and Cosmetic Act.

Compounding pharmacies that produce MOTS-c for clinical use are operating under sections 503A and 503B of the FD&C Act, which carry specific requirements around bulk drug substance use. Those sections do not automatically permit the compounding of any peptide a prescriber requests.

The Mitochondrial Genome Connection and Its Legal Novelty

Most FDA-regulated peptides are encoded by the nuclear genome or are entirely synthetic. MOTS-c is unusual because its coding sequence resides in mitochondrial DNA. That biological novelty has no direct regulatory consequence, but it does mean there is no established pharmacopeial monograph, no reference listed drug, and no prior FDA product review to anchor a compounding pharmacy's legal analysis.

FDA Approval History for MOTS-c

MOTS-c has never been approved by the FDA. Period.

A search of the Drugs@FDA database returns zero results for "MOTS-c" or "mitochondrial open reading frame twelve S rRNA type-c" as an approved new drug application, abbreviated new drug application, or biologics license application. No sponsor has submitted an NDA for a MOTS-c drug product, and no IND approval for large-scale human trials has been publicly announced as of the date of this article.

No NDA, No BLA, No 505(b)(2)

The three primary regulatory pathways to lawful drug marketing in the United States are the NDA (Section 505(b)(1) or 505(b)(2)) and the BLA. MOTS-c has not traveled any of these pathways. Without an approved NDA or BLA, a finished drug product containing MOTS-c cannot be legally marketed as a therapeutic in the United States by a pharmaceutical manufacturer. FDA Drugs@FDA database: https://www.accessdata.fda.gov/scripts/cder/daf/

Investigational New Drug Applications

Clinical research on unapproved substances requires an IND filed with FDA's Center for Drug Evaluation and Research. No publicly registered IND for MOTS-c in human subjects is listed in ClinicalTrials.gov as of mid-2025. Small exploratory studies have been conducted in South Korea and Japan, but none of those constitute a U.S. IND. A Phase I dose-escalation study would need to precede any Phase II or III efficacy trial under FDA jurisdiction.

The 2015 Origin Point and the Ten-Year Gap

From the time Lee et al. Published the foundational mouse data in 2015 to 2025, a full decade has passed without an approved pharmaceutical-grade MOTS-c product reaching the U.S. Market. That gap reflects both the early stage of the science and the absence of a large commercial sponsor willing to fund the estimated $50-100 million cost of a Phase I-III development program for a metabolic peptide with no patent exclusivity from a natural sequence.

Compounding Legal Status Under 503A and 503B

Compounding pharmacies operate under two distinct federal frameworks. Section 503A covers traditional compounding for individual patients with valid prescriptions. Section 503B covers outsourcing facilities that produce larger batches. Both sections have specific rules about which bulk drug substances can be used.

The Bulk Drug Substance Nomination Process

FDA maintains three lists relevant to bulk substances used in compounding:

1. Category 1: Bulk substances nominated for evaluation (under review).
2. Category 2: Bulk substances that raise significant safety concerns and are not permitted.
3. The 503B Bulks List: Substances affirmatively approved for use by outsourcing facilities.

MOTS-c does not appear on any of these lists. It has not been formally nominated for Category 1 review, does not appear on the Category 2 restriction list, and is not on the 503B Bulks List. FDA 503B Bulks List: https://www.fda.gov/drugs/human-drug-compounding/bulk-drug-substances-used-compounding-outsourcing-facilities

What Absence From the Lists Actually Means

Absence from the 503B Bulks List is not a green light. FDA's position, stated in the agency's 2016 draft guidance on bulk drug substances for 503A compounding, is that a pharmacy may use a bulk drug substance only if it appears on the FDA-approved 503A bulks list, is a component of an FDA-approved drug, or has a United States Pharmacopeia (USP) monograph. MOTS-c satisfies none of those three criteria. FDA Draft Guidance on 503A Bulk Drug Substances: https://www.fda.gov/media/94399/download

A pharmacy compounding MOTS-c for patient use is therefore proceeding without explicit regulatory authorization for the bulk substance. That exposes both the pharmacy and the prescribing clinician to enforcement risk.

Synthetic Peptide Guidance From 2015 and 2022

FDA issued a draft guidance in 2015 specifically addressing synthetic peptides in compounding. That guidance flagged concerns about peptides that: (a) have no approved drug product equivalent, (b) lack established pharmacopeial standards, and (c) present uncertain safety profiles from limited human data. MOTS-c meets all three of those criteria. The 2022 update to peptide compounding guidance did not add MOTS-c to any approved list. FDA Guidance on Compounding with Bulk Substances: https://www.fda.gov/drugs/human-drug-compounding/compounding-laws-and-policies

The HealthRX clinical team uses a four-factor framework when evaluating any unlisted peptide for prescribing decisions. The factors are: (1) Is there a publicly registered IND or approved NDA? (2) Does the bulk substance appear on an FDA-approved compounding list? (3) Is there a USP monograph? (4) Has at least one published Phase I human safety study been completed? For MOTS-c, all four answers are currently "no." A "no" on any single factor warrants heightened caution; four consecutive "no" answers means prescribing carries substantial regulatory and clinical uncertainty.

What the MOTS-c "Label" Actually Is

There is no FDA-approved label for MOTS-c.

When researchers or online vendors refer to a "MOTS-c label," they are describing either a certificate of analysis (CoA) from a research chemical supplier, a custom compounding label a pharmacy attaches to a vial, or promotional copy from a peptide vendor. None of these constitute an FDA-approved prescribing information document.

Certificate of Analysis vs. Prescribing Information

A CoA from a chemical supplier like Bachem or PolyPeptide Group confirms purity, sequence, and mass spectrometry data. It is a quality document, not a regulatory authorization. It does not specify a therapeutic indication, a dosing regimen, contraindications, warnings, or adverse effect profiles in the way FDA-approved prescribing information does.

What Would Be Required for a Legitimate Label

For MOTS-c to carry an FDA-approved label, a sponsor would need to complete the full NDA process, including preclinical toxicology, Phase I safety, Phase II dose-finding, and Phase III efficacy trials. The resulting prescribing information would include sections on indications and usage, dosage and administration, contraindications, warnings and precautions, adverse reactions, drug interactions, use in specific populations, and pharmacokinetics. None of that data exists in the public record at the standard required for NDA approval.

Compounding Pharmacy Labels

Under 21 CFR 211.68 and state board of pharmacy regulations, a compounding pharmacy must label each compounded preparation with the patient's name, prescriber's name, lot number, beyond-use date, and strength. These labels are compliance documents, not FDA-approved labeling. Seeing a professional-looking vial label on a compounded MOTS-c product does not confer any form of FDA authorization.

Available Safety Data for MOTS-c

The safety database for MOTS-c in humans is thin. That statement is not pessimism but a factual description of where the science stands in 2025.

Animal Data

The 2015 Lee et al. Study demonstrated that systemic MOTS-c injection (0.5 mg/kg intraperitoneally) reduced adiposity and improved insulin sensitivity in C57BL/6 mice over 8 weeks without observed toxicity. [Lee C et al. Cell Metabolism 2015: https://pubmed.ncbi.nlm.nih.gov/25738459/] A follow-up study by the same group published in Nature Communications in 2019 (N=varies by arm) showed MOTS-c reduced age-related physical decline in older mice. These are important mechanistic signals, but rodent pharmacokinetics differ enough from human physiology that direct dose extrapolation is unreliable.

Early Human Signals

A small human study conducted in Japan examined circulating MOTS-c levels as a biomarker (not a therapeutic) in type 2 diabetes patients. Circulating MOTS-c was lower in diabetic subjects compared to controls, a finding consistent with the peptide's proposed metabolic role but not evidence that exogenous administration is safe or effective. No formal Phase I dose-escalation study has published its primary results in a peer-reviewed journal indexed on PubMed as of mid-2025.

Adverse Effect Profile

Because no controlled human trial has completed, there is no FDA-adjudicated adverse event database for MOTS-c. Reports circulating in peptide-prescribing communities describe injection-site reactions, transient fatigue, and rare reports of nausea. These are anecdotal and have not been adjudicated through any IRB-approved safety monitoring framework. Without a proper Phase I study, the maximum tolerated dose, the dose-limiting toxicities, and the half-life in human plasma are not established to the standard FDA requires.

What the Absence of Phase III Data Means Clinically

The STEP-1 trial (N=1,961) demonstrated that semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% with placebo, a difference that reached P<0.001 and came from a rigorous RCT design. Wilding JPH et al. NEJM 2021: https://www.nejm.org/doi/full/10.1056/NEJMoa2032183 No comparable trial exists for MOTS-c. Prescribers comparing MOTS-c to approved metabolic therapies are comparing anecdote to evidence.

How FDA Enforcement Has Treated Unapproved Peptides

FDA's enforcement posture toward compounded peptides has tightened significantly since 2021. The agency has issued warning letters to compounding pharmacies for producing peptides including BPC-157, epithalon, and selank without bulk substance authorization.

Warning Letters as Precedent

A 2023 FDA warning letter to a 503A pharmacy (publicly available on FDA's website) cited the production of unapproved peptides as violations of the FD&C Act, specifically noting that using bulk drug substances not on the 503A approved list constitutes adulteration and misbranding. FDA Warning Letters Database: https://www.fda.gov/inspections-compliance-enforcement-and-criminal-investigations/compliance-actions-and-activities/warning-letters While these letters did not name MOTS-c specifically, the legal reasoning applies equally to any unlisted bulk peptide.

The Adulteration and Misbranding Standard

Under 21 U.S.C. 351 and 352, a drug is adulterated if it is not manufactured under current Good Manufacturing Practice (cGMP), and it is misbranded if its labeling is false or misleading or omits required information. A compounded MOTS-c vial with only a basic pharmacy label and no approved prescribing information satisfies the misbranding definition.

State Board of Pharmacy Jurisdiction

State pharmacy boards have independent authority to discipline pharmacies and pharmacists. Several states, including California and Florida, have adopted rules that mirror or exceed FDA's bulk substance requirements. A pharmacy in those states compounding MOTS-c may face state-level disciplinary action even if federal enforcement action has not been initiated.

The Prescriber's Exposure

Clinicians who prescribe MOTS-c face a different but overlapping set of risks compared to the compounding pharmacy.

Off-Label Prescribing vs. Prescribing an Unapproved Drug

Off-label prescribing is legal in the United States when the drug is FDA-approved for at least one indication. Prescribing an unapproved drug is a distinct category. MOTS-c is not approved for any indication, so prescribing it is not "off-label" in the conventional sense. It is prescribing an unapproved investigational substance outside of an IND framework.

Medical Board Risk

State medical boards can investigate prescribing practices that fall outside the standard of care. Prescribing a substance with no approved indication, no established dosing, and no completed Phase I safety study may be characterized as falling below that standard. The American Association of Clinical Endocrinology (AACE) and the Endocrine Society have not published guidelines endorsing MOTS-c for any therapeutic use. Endocrine Society Clinical Practice Guidelines: https://www.endocrine.org/clinical-practice-guidelines

Documentation and Informed Consent

If a clinician elects to prescribe MOTS-c despite these limitations, the minimum documentation standard should include: a written informed consent explaining that the compound lacks FDA approval, that safety data are limited to animal studies and small human observational work, and that the legal status of the compounded preparation is unsettled. That documentation does not eliminate risk but provides evidence that the prescriber met an informed consent standard.

Pathways to Legitimacy: What Would Have to Change

For MOTS-c to achieve a clear legal status, one of three things would need to happen.

First, a pharmaceutical sponsor could file an IND, complete Phase I-III trials, and submit an NDA. Given the lack of patent protection on a naturally occurring sequence, commercial incentive is limited. An academic medical center or NIH-funded group could file an IND for investigational use, which would make administration lawful within the trial but not outside it.

Second, FDA could add MOTS-c to the 503A or 503B bulks nomination and approval process. That requires a formal nomination from a stakeholder, FDA evaluation of safety and clinical need, and public comment. No such nomination has been submitted as of 2025.

Third, the United States Pharmacopeia could develop a monograph for MOTS-c, which would satisfy the USP-monograph prong of the 503A bulk substance rule. USP monograph development requires manufacturer participation and stability data that do not yet exist in the public record.

None of these pathways are imminent based on publicly available information.